Novartis Pumps $15M Into Israeli Stem Cell Research Firm
The Swiss drug maker Novartis will invest an extra $15 million in Gamida Cell, an Israeli developer of stem cell therapies, Gamida said.
Novartis last year invested $35 million in the company for a 15 percent stake, the Tachles Jewish weekly of Switzerland reported this week. The deal could reach $600 million if Novartis exercises a buyout option that expires in 2016.
The $15 million investment will be used to advance Gamida Cell’s clinical programs, including the development of an experimental treatment for patients with high risk hematological malignancies, or blood cancers such as leukemia and lymphoma and sickle cell disease.
Gamida plans to initiate a Phase III clinical trial with NiCord in mid-2016, according to Reuters.
Novartis will not have rights or options to Gamida Cell products or technology under the terms of the agreement.
Other Gamida shareholders include Israeli firms that have been the subjects of politically motivated divestment by European business, including Elbit Imaging and Teva Pharmaceutical Industries.
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly.
— Rachel Fishman Feddersen, Publisher and CEO
Join our mission to tell the Jewish story fully and fairly.
